The FDA has approved agents that target IL-6 and downstream signaling pathways, such as IL-6, IL-6R, and JAKs, for the treatment of inflammatory diseases and myeloproliferative neoplasms 10. This evidence concerns the gene IL6R and myeloproliferative neoplasm.